Ferring has gained international recognition over the last 25 years. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.

Ferring aims to further strengthen its position in the coming years through additional alliances with other pharmaceutical and biotech companies, as well as academic institutions.

To meet the company’s mid- and long-term goals Ferring invests heavily in research and development. In addition, we actively search for in-licensing opportunities, product and company acquisitions.

Ferring’s Business Development activities have led to a variety of mergers, acquisitions, license arrangements, and development collaborations with companies around the world, including transactions with the following companies (please click on the links to view the related press releases):

• Astellas Pharma Inc.
• Auxilium Pharmaceuticals, Inc.
• BioGaia AB
• Conaris Research Institute AG
• Cosmo Pharmaceuticals SpA
• Dupomar S.A.
• Novartis Pharma AG
• Savient Pharmaceuticals, Inc.